Antipsychotics

Before the mid-twentieth century, patients suffering from schizophrenia and other psychotic disorders were largely confined to asylums, managed with physical restraint, hydrotherapy, or insulin-induced comas—interventions that addressed behavior without touching the underlying neurobiology. The discovery of chlorpromazine in the early 1950s marked a watershed moment, demonstrating for the first time that a chemical agent could specifically reduce hallucinations, delusions, and disorganized thought. This breakthrough catalyzed the field of psychopharmacology and led to the deinstitutionalization movement, fundamentally reshaping psychiatric care worldwide.

The central question that antipsychotic pharmacology seeks to answer is deceptively simple: how can we selectively modulate dopaminergic—and increasingly serotonergic—neurotransmission to alleviate psychotic symptoms while minimizing the movement disorders, metabolic derangements, and sedation that accompany broad receptor blockade? Understanding the evolution from first-generation to second-generation and now third-generation agents reveals both the power and the limitations of our current neurochemical models of psychosis.

Antipsychotic drugs are broadly classified into two generations, with a functional third category emerging around dopamine partial agonism. All antipsychotics share a common pharmacological thread: modulation of dopamine D₂ receptors in the mesolimbic pathway. However, their differing receptor binding profiles—particularly at serotonin 5-HT_2A receptors, muscarinic receptors, histamine H₁ receptors, and α₁-adrenergic receptors—account for the vast differences in their side-effect profiles and clinical utility.

The diagram above illustrates why selectivity is the central challenge of antipsychotic pharmacology. The mesolimbic pathway projects from the ventral tegmental area (VTA) to the nucleus accumbens and is thought to mediate the positive symptoms of psychosis—hallucinations, delusions, and thought disorder. Blockade here is therapeutically desirable. However, because D₂ receptors are distributed across all four pathways, non-selective antagonism inevitably disrupts motor control via the nigrostriatal pathway (causing EPS and tardive dyskinesia), impairs executive function and motivation via the mesocortical pathway, and elevates prolactin via the tuberoinfundibular pathway. Second-generation agents mitigate some of these effects through concurrent 5-HT₂A antagonism, which disinhibits dopamine release in the nigrostriatal and mesocortical pathways, partially restoring dopaminergic tone where it is needed.

The therapeutic and adverse effects of antipsychotics can be understood through their receptor binding profiles. While all clinically effective antipsychotics interact with D₂ receptors, their affinities at other receptor subtypes—including serotonin 5-HT₂A, muscarinic M₁, histamine H₁, and α₁-adrenergic receptors—determine the spectrum of clinical effects. The concept of receptor occupancy is critical: PET imaging studies have demonstrated that antipsychotic response typically requires 60–80% D₂ occupancy in the striatum, while occupancy above 80% is associated with a steep increase in extrapyramidal side effects.

Multi-Receptor Binding: Predicting Side Effects

The pharmacological distinction between first- and second-generation agents extends beyond simple receptor affinity to include the concept of fast dissociation kinetics. Kapur and Seeman proposed that atypical antipsychotics like clozapine and quetiapine dissociate rapidly from D₂ receptors, allowing physiological dopamine surges (e.g., in the nigrostriatal pathway) to still transiently activate the receptor. This "hit-and-run" binding pattern may explain their lower EPS liability without invoking 5-HT₂A antagonism as the sole explanation. Meanwhile, aripiprazole represents a different paradigm entirely: as a D₂ partial agonist, it activates the receptor at roughly 25–30% of full agonist efficacy—enough to prevent psychosis (by competing with endogenous dopamine in hyperactive circuits) while maintaining sufficient basal tone in hypoactive pathways to avert EPS and hyperprolactinemia.

First-Generation (Typical) Antipsychotics

First-generation antipsychotics (FGAs) are further divided into high-potency and low-potency agents. High-potency agents such as haloperidol and fluphenazine have very high D₂ affinity relative to other receptors, producing potent antipsychotic effects at low milligram doses but causing significant EPS. Low-potency agents like chlorpromazine and thioridazine require higher doses and bind more broadly to muscarinic, histaminic, and α-adrenergic receptors, resulting in more sedation, anticholinergic effects, and orthostatic hypotension but comparatively less EPS. This relationship is sometimes remembered through the heuristic: high potency equals high EPS, low potency equals high sedation and anticholinergic burden.

Second-Generation (Atypical) Antipsychotics

Consider the following clinical scenario: a 28-year-old male presents with a first episode of schizophrenia characterized by auditory hallucinations and paranoid delusions. He has no significant medical history, a BMI of 22, and is employed as an electrician—a job requiring alertness and fine motor coordination. How would you approach antipsychotic selection?

Beyond the predictable receptor-mediated side effects discussed in Section 4, antipsychotics carry several serious safety concerns that require heightened vigilance. These range from acute medical emergencies such as neuroleptic malignant syndrome (NMS) to insidious metabolic derangements that accumulate over years of treatment, contributing to the reduced life expectancy observed in patients with chronic psychotic disorders.

While dopamine-centric pharmacology has dominated antipsychotic development for over six decades, research increasingly recognizes the limitations of the dopamine hypothesis in explaining the full spectrum of schizophrenia, particularly negative symptoms (anhedonia, social withdrawal, alogia) and cognitive deficits. The glutamate hypothesis, based on the observation that NMDA receptor antagonists like phencyclidine (PCP) and ketamine produce a full spectrum of schizophrenia-like symptoms, has driven development of novel targets beyond the dopamine system.

The approval of xanomeline-trospium (KarXT) in September 2024 represents a paradigm shift—for the first time, an antipsychotic that does not directly interact with D₂ receptors has demonstrated efficacy in randomized controlled trials. Xanomeline is a muscarinic M₁/M₄ agonist, and trospium is a peripheral muscarinic antagonist added to mitigate the GI side effects of cholinergic stimulation. This mechanistic departure opens the door to entirely new pharmacological strategies and underscores the heterogeneity of the neurobiology underlying psychosis.